Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab Monotherapy for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection With Only and Mainly B Lymphocytes of EBV Infection

NCT05384743 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT05384743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05384743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab Monotherapy for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection With Only and Mainly B Lymphocytes of EBV Infection
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
February 1, 2022
Completion date
April 1, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic active epstein-barr virus infection, secondary hemophagocytic lymphohistiocytosis